Sat, Apr 19, 2014, 7:49 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • jsblvbjb jsblvbjb Mar 12, 2013 2:29 PM Flag

    Wake up people! Our "partner" was just bought by a 17 billion dollar pharma!!!!

    Folks, this is "money." It's not bragging rights or expected clinical data. Cold, hard cash, and that's going to move the stock price substantially!
    pianoman

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Some people just don`t know how to connect the dots-Either Iplex is going to be sold or the whole company-Shire can afford it.I`m not sure The board will let Iplex go for anything less than a kings ransom,so it might be a better deal for Shire to try and buy Insmed all together.

      Sentiment: Strong Buy

    • ...And that's the other one!

      Sentiment: Strong Buy

    • On May 25, 2012, the Company entered into an agreement with Premacure
      Holdings AB and Premacure AB of Sweden (collectively, "Premacure")
      pursuant to which the Company agreed to grant to Premacure an exclusive,
      worldwide license to develop manufacture and commercialize IGF-1, with
      its natural binding protein, IGFBP-3, for the prevention and treatment
      of complications of preterm birth. (the " Premacure License Agreement").
      Premacure is currently focusing on retinopathy of prematurity. IGF- and
      IGFBP-3 were previously developed by the Company at higher
      concentrations as IPLEX®. The license is subject to the Company's
      receipt of a consent and waiver from Tercica, Inc., now the Ipsen Group
      ("Tercica") and from Genentech, Inc., now owned by Roche ("Genentech"),
      of certain rights granted by the Company to Tercica and Genentech under
      the Settlement, License and Development Agreement dated March 5, 2007
      (the "Waivers"). The Premacure License Agreement includes diligence
      milestones and royalty payments on prospective product sales.

      Sentiment: Strong Buy

    • In 2011,Insmed sold the rights to Premacure.
      This thread is hype that does not exist.because Shire has the rights means what to INSM SH? Nothing

    • Very interesting that Shire be interested in such small indication of ROP. Good to have such a large partner now. Well maybe they are interested in getting all rights for IPLEX....=) That would be a huge plus for us

    • That is great news...wonder if yesterday's run up was a leak on the news?

      Cheers! Windy

    • For a company that has basically removed iPlex from its marketing materials, including their website, you seem convinced this is big news and this will help the SP.

      As a long suffering long, I am not expecting this to have ANY sustainable impact on the SP soon, if at all. I gave up on iPlex when Insmed bought Transave. As usual, pianoman, you over-hype news.

      INSM's SP is dependent upon the Arikace trials, and if you believe otherwise, then maybe you still believe in Santa Claus and the Tooth Fairy.

    • (Reuters) - Shire increased its investment in rare diseases on Tuesday by acquiring privately held Swedish biotech firm Premacure, which is developing a drug for a potentially blinding eye disorder in premature babies.

      Britain's third biggest drugmaker did not reveal how much it was paying for the Uppsala-based business but said it would pay a sum upfront followed by contingent payments based on clinical development and commercial success.

      The acquisition takes Shire into the new area of neonatology - the treatment of sick or premature newborn infants - and expands its already substantial presence in rare diseases.

      Treating diseases that affect only a small number of patients is a growing focus for many drug companies given the high prices that can be achieved.

      Premacure, which was launched in 2006, has an experimental protein replacement medicine in mid-stage Phase II clinical development for the prevention of retinopathy of prematurity (ROP).

      Normal full-term babies produce enough growth factors on their own to prevent diseases like ROP. But those born before 31 weeks may lack chemicals such as insulin-like growth factor 1 (IGF-1), which can result in life-long complications like ROP.

      Shire said its human genetic therapies unit would continue with the Phase II study, the primary goal of which is to restore the IGF-1 levels in premature infants to those found in babies born at full term.

    • Who is Our "partner" Jesse.. TIA

 
INSM
13.41+0.88(+7.02%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.